Apyx Medical shareholders approve 2026 incentive plan
Apyx Medical Corporation held its 2026 Annual Meeting of Stockholders on August 6, 2026.
Rhea-AI Filing Summary
Apyx Medical Corporation held its 2026 Annual Meeting of Stockholders on August 6, 2026. Stockholders elected five directors and ratified RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 29,814,618 votes cast in favor.
Stockholders also approved a non-binding advisory resolution on executive compensation, receiving 21,458,554 votes in favor, and approved the Company’s 2026 Share Incentive Plan, which obtained 16,186,776 votes cast in favor, 2,755,882 votes against, and 3,276,000 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
broker non-votes financial
non-binding advisory resolution regulatory
independent registered public accounting firm regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What key items did Apyx Medical (APYX) stockholders approve at the 2026 Annual Meeting?
Did Apyx Medical (APYX) stockholders ratify the independent auditor for 2026?
How did Apyx Medical (APYX) stockholders vote on executive compensation in 2026?
Which directors were elected to the Apyx Medical (APYX) board at the 2026 meeting?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As described under Item 5.07 of this Current Report on Form 8-K, Apyx Medical Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company’s stockholders approved the adoption of the Company’s 2026 Share Incentive Plan (the “2026 Plan”).
A summary of the 2026 Plan is contained, under the heading “Approval of the 2026 Share Incentive Plan”, in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on June 26, 2026 (the “Proxy Statement”).
The foregoing description of the 2026 Plan is qualified in its entirety by reference to the full text of the 2026 Plan that is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On August 6, 2026, the following proposals were submitted to the stockholders of the Company at its Annual Meeting: (1) the election of five (5) directors; (2) the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026; (3) the approval of a non-binding advisory resolution supporting the compensation of the Company’s named executive officers; and (4) the approval of the Company’s 2026 Share Incentive Plan.
The proposals are described in more detail in the Proxy Statement.
The following are the final voting results for each proposal:
| Proposal 1: | The Company’s stockholders elected each of the following five (5) directors to serve on the Board of Directors of the Company until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, by the following vote: |
| Name | Number
of Votes Cast in Favor |
Number
of Votes Cast Against |
Number
of Votes Abstained |
Broker Non-Votes | ||||
| Stavros G. Vizirgianakis | 18,051,294 | 4,083,005 | 84,359 | 7,677,267 | ||||
| Charles D. Goodwin | 21,338,164 | 788,416 | 92,078 | 7,677,267 | ||||
| Lawrence J. Waldman | 21,332,747 | 718,782 | 167,129 | 7,677,267 | ||||
| Minnie Baylor-Henry | 15,400,914 | 6,650,608 | 167,136 | 7,677,267 | ||||
| Wendy Levine | 15,395,258 | 6,656,271 | 167,129 | 7,677,267 |
| Proposal 2: | The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following vote: |
| Number
of Votes Cast in Favor |
Number
of Votes Cast Against |
Number
of Votes Abstained |
Broker Non-Votes | |||
| 29,814,618 | 31,610 | 49,697 | - |
| Proposal 3: | The Company’s stockholders approved a non-binding advisory resolution supporting the compensation of the Company’s named executive officers, by the following vote: |
| Number
of Votes Cast in Favor |
Number
of Votes Cast Against |
Number
of Votes Abstained |
Broker Non-Votes | |||
| 21,458,554 | 669,298 | 90,806 | 7,677,267 |
| Proposal 4: | The Company’s stockholders approved the Company’s 2026 Share Incentive Plan, by the following vote: |
| Number
of Votes Cast in Favor |
Number
of Votes Cast Against |
Number
of Votes Abstained |
Broker Non-Votes | |||
| 16,186,776 | 2,755,882 | 3,276,000 | 7,677,267 |
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 10.1 | Apyx Medical Corporation 2026 Share Incentive Plan | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 7, 2026 | APYX MEDICAL CORPORATION | |
| By: | /s/ Matthew Hill | |
| Matthew Hill | ||
| Chief Financial Officer, Secretary and Treasurer | ||